CA2018388A1 - Therapeutic agent for tinea - Google Patents
Therapeutic agent for tineaInfo
- Publication number
- CA2018388A1 CA2018388A1 CA002018388A CA2018388A CA2018388A1 CA 2018388 A1 CA2018388 A1 CA 2018388A1 CA 002018388 A CA002018388 A CA 002018388A CA 2018388 A CA2018388 A CA 2018388A CA 2018388 A1 CA2018388 A1 CA 2018388A1
- Authority
- CA
- Canada
- Prior art keywords
- tinea
- therapeutic agent
- tea
- tea extract
- theaflavin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Abstract
Abstract of the Disclosure Disclosed is a therapeutic agent for tinea, which comprises a tea extract as a main component. This therapeutic agent has a sufficient antifungal action to tinea fungus, and since the main component is a natural product dialy drunk, it is confirmed that the therapeutic agent has a high safety.
Description
" ' 20~388 THERAPEUTIC AGENT FOR TINEA
Background of the Invention The present invention relates to a therapeutic agent for tinea. More particularly, the present invention relates to a therapeutic agent for tinea, which comprises a tea extract as a main component.
As diseases caused by the parasitism of tinea fungus (filamentous fungus belonging to the genus Trichophyton), there can be mentioned tinea pedis (foot ringworm), tinea capitis (head ringworm), tinea corpis (body ringworm), tinea cruris (inguinal ringworm), tinea manis (hand ring-worm), tinea unguium (nail ringworm) and tinea scrotis.
These diseases are generally called "tinea", a kind of skin diseases peculiar to men. Iodine tincture, salicylic acid vaseline, tar paste, Griseofulvin ointment, ichthyol/zinc oxide oil, aqueous boric acid and other medicines are known as therapeutic agents for remedy of tinea. However, therapeutic effects of these agents are not satisfactory, and it often happens that even if tinea is once seemingly cured, it recurs and becomes chronic. Moreover, direct external application of these agents to the affected parts involves troubles such as toxicity and skin irritation. Therefore, development of an effective therapeutic agent for tinea, " 2 0 ~ ~ 3 8 8 which can be applied to the affected parts with safety, is eagerly desired.
; Summarv of the Invention Inventors searched for a substance having an intended therapeutic affect among natural products, apart from chemical synthetic products, and as the result, it was found that the target substance is contained in tea and tea polyphenols. Inventors have now completed the present invention based on this finding.
More specifically, in accordance with the present invention, it is provided a therapeutic agent for tinea, which comprises a tea extract as a main component.
Detailed Description of the Invention A principal component of the tea extract is tea polyphenol compounds, and said tea polyphenol compounds include the tea catechin compounds represented by the general formula (I) given below and the theaflavin compounds represented by the general formula (II) given below, and also thearubigin:
OH
H`l?~oll , .................. (I) in which Rl is a hydrogen atom or a hydroxy group and R2 is a hydrogen atom or a 3,4,5-trihydroxy benzoyl group;
and " ~ 20~8388 OH
OR ~
110 ~011 : ~0 H0 ~ X - 0H , ..................... (II) 01~
in which R3 and R4 are, each independently from the other, a hydrogen atom or a 3,4,5-trihydroxy benzoyl group.
Particular examples of the tea catechin compounds represented by the general formula ~I) include:
(-)epicatechin, which is a compound of the formula (I) with Rl = H and R2 = H; (-)epigallocatechin, which is a compound of the formula (I) with Rl = OH and R2 = H;
(-)epicatechin gallate, which is a compound of the formula (I) with Rl = H and R2 = 3,4,5-trihydroxy benzoyl group; and (-)epigallocatechin gallate, which is a compound of the formula (I) with Rl = OH and R2 = 3,4,5-trihydroxy benzoyl group. Particular examples of the theaflavin compounds include: free theaflavin, which is a compound of the formula (II) with R3 = H and R4 = H; theaflavin monogallate A, which is a compound of the formula (II) with R3 = 3,4,5-trihydroxy benzoyl group and R4 = H;
theaflavin monogallate B, which is a compound of the formula (II) with R3 = H and R4 = 3,4,5-trihydroxy benzoyl group; and theaflavin digallate, which is a compound of the formula (II) with R3 = 3,4,5-trihydroxy - ~ 20~8388 benzoyl group and R4 = 3,4,5-trihydroxy benzoyl group.
The above described tea polyphenol compoun~s can be prepared from tea leaves as the starting material and a method for the preparation thereof and a typical example of the product composition are described, for example, in Japanese Patent Kokai 59-219384, 60-13780 and 61-130285, etc.
When the therapeutic agent for tinea according to the present invention is used, the concentration of the tea extract as the main component can be determined according to the contents of tea polyphenols such as catechins and theaflavins. Namely, the concentration of the tea extract is determined so that the tea polyphenol content is 0.1 to 500 ppm, preferably about 2 to about 100 ppm. More specifically, an extract obtained by extracting starting tea at 5 to 0.001~, preferably 1 to 0.01%, is used. The form of the therapeutic agent for tinea includes not only a liquid but also an ointment prepared according to customary procedures.
The therapeutic agent for tinea according to the present invention has a sufficient antifungal action to tinea fungus, and since the therapeutic agent of the present invention comprises as a main component the natural product which is daily drunk in considerable quantities and the safety of which is thus confirmed, the ; 20~8388 therapeutic agent is used without anxiety.
Therefore, the therapeutic agent for tinea according to the present invention has a very high practlcal utility.
The present invention will now be described in detail with reference to the following examples.
Example 1 A 20% (w/v) phosphate buffer extract of cGmmercially available black tea was preapred, and the extract was appropriately diluted and used. Trichophyton mentagroPhYtes TIMM 1188 strain and Trichophyton rubrum TIMM 1216 strain were used as the tinea fungus. The fungus was slant-cultured at 27C for 10 days, and Tween 80 (0.05%)-added physiological saline solution was added to the culture product to separate and float conidiophores. The suspension was filtered through gauze, and a fungus liquid was prepared based on the absorbance at 530 nm by using a turbidimeter (CORONA UT-ll). The following tests were carried out by using this fungus liquid.
1) Antifungal Test An agar plate containing 5% or 2.5% of the tea extract was prepared by using yeast morphology agar (supplied by Difco), and the plate was inoculated with 5 ~Q of the fungus liquid containing 1 x 10 to 1 x 106 of coni-diophores per mQ by the spot method, and culturing was conducted at 27 to 30C for 2 or 4 days and the evaluation 2 0 ~ 8 3 8 8 was made.
As the result, it was found that the tea extract showed apparently an antifungal effect on the tinea fungus, and in the control group, sufficient growth of hyphae was observed by 4 days' culturing, while no growth of hyphae was observed at all in the tea extract-added group.
2) Fungicidal Test Equal amounts of a twice~concentrated Sabouraud culture medium in which conidiophores were floated and a tea extract (5% or 2.5~) were mixed, and culturing was conducted. A Sabouraud agar plate was inoculated with 5 ~Q of the culture medium at predetermined time intervals by the spot method and the growth of the fungus was observed.
As the result, it was found that the fungicidal effect of the tea extract had a concentration dependency, but if the contact time was prolonged (48 to 72 horus), a fungicidal effect was manifested even at a low concen-tration.
Example 2 In Example 1-1), an agar plate in which a predeter-mined amount of epigallocatechin gallate ~EGCg) or theaflavin digallate (TF3) was incorporated instead of the tea extract was prepared, and 5 ~Qof a suspension of 20~8388 conidiophores (1 x 106 7/mQ) was inoculated on the plate by the spot method. Other procedures were the same as in Example 1. The results are shown in Table 1.
` 2018388 ~o ~ + + + +
~o~
E3 ol + + , + +
~1 u~l tn o ~I o + + + +
U
.~_ ~ o + + + +
~0 u~l + I +
O U~
, ~1 , , O
~I ~
R ,:~ ~ ~ ~ ~ O S
~0 ~n .~ ;
~1
Background of the Invention The present invention relates to a therapeutic agent for tinea. More particularly, the present invention relates to a therapeutic agent for tinea, which comprises a tea extract as a main component.
As diseases caused by the parasitism of tinea fungus (filamentous fungus belonging to the genus Trichophyton), there can be mentioned tinea pedis (foot ringworm), tinea capitis (head ringworm), tinea corpis (body ringworm), tinea cruris (inguinal ringworm), tinea manis (hand ring-worm), tinea unguium (nail ringworm) and tinea scrotis.
These diseases are generally called "tinea", a kind of skin diseases peculiar to men. Iodine tincture, salicylic acid vaseline, tar paste, Griseofulvin ointment, ichthyol/zinc oxide oil, aqueous boric acid and other medicines are known as therapeutic agents for remedy of tinea. However, therapeutic effects of these agents are not satisfactory, and it often happens that even if tinea is once seemingly cured, it recurs and becomes chronic. Moreover, direct external application of these agents to the affected parts involves troubles such as toxicity and skin irritation. Therefore, development of an effective therapeutic agent for tinea, " 2 0 ~ ~ 3 8 8 which can be applied to the affected parts with safety, is eagerly desired.
; Summarv of the Invention Inventors searched for a substance having an intended therapeutic affect among natural products, apart from chemical synthetic products, and as the result, it was found that the target substance is contained in tea and tea polyphenols. Inventors have now completed the present invention based on this finding.
More specifically, in accordance with the present invention, it is provided a therapeutic agent for tinea, which comprises a tea extract as a main component.
Detailed Description of the Invention A principal component of the tea extract is tea polyphenol compounds, and said tea polyphenol compounds include the tea catechin compounds represented by the general formula (I) given below and the theaflavin compounds represented by the general formula (II) given below, and also thearubigin:
OH
H`l?~oll , .................. (I) in which Rl is a hydrogen atom or a hydroxy group and R2 is a hydrogen atom or a 3,4,5-trihydroxy benzoyl group;
and " ~ 20~8388 OH
OR ~
110 ~011 : ~0 H0 ~ X - 0H , ..................... (II) 01~
in which R3 and R4 are, each independently from the other, a hydrogen atom or a 3,4,5-trihydroxy benzoyl group.
Particular examples of the tea catechin compounds represented by the general formula ~I) include:
(-)epicatechin, which is a compound of the formula (I) with Rl = H and R2 = H; (-)epigallocatechin, which is a compound of the formula (I) with Rl = OH and R2 = H;
(-)epicatechin gallate, which is a compound of the formula (I) with Rl = H and R2 = 3,4,5-trihydroxy benzoyl group; and (-)epigallocatechin gallate, which is a compound of the formula (I) with Rl = OH and R2 = 3,4,5-trihydroxy benzoyl group. Particular examples of the theaflavin compounds include: free theaflavin, which is a compound of the formula (II) with R3 = H and R4 = H; theaflavin monogallate A, which is a compound of the formula (II) with R3 = 3,4,5-trihydroxy benzoyl group and R4 = H;
theaflavin monogallate B, which is a compound of the formula (II) with R3 = H and R4 = 3,4,5-trihydroxy benzoyl group; and theaflavin digallate, which is a compound of the formula (II) with R3 = 3,4,5-trihydroxy - ~ 20~8388 benzoyl group and R4 = 3,4,5-trihydroxy benzoyl group.
The above described tea polyphenol compoun~s can be prepared from tea leaves as the starting material and a method for the preparation thereof and a typical example of the product composition are described, for example, in Japanese Patent Kokai 59-219384, 60-13780 and 61-130285, etc.
When the therapeutic agent for tinea according to the present invention is used, the concentration of the tea extract as the main component can be determined according to the contents of tea polyphenols such as catechins and theaflavins. Namely, the concentration of the tea extract is determined so that the tea polyphenol content is 0.1 to 500 ppm, preferably about 2 to about 100 ppm. More specifically, an extract obtained by extracting starting tea at 5 to 0.001~, preferably 1 to 0.01%, is used. The form of the therapeutic agent for tinea includes not only a liquid but also an ointment prepared according to customary procedures.
The therapeutic agent for tinea according to the present invention has a sufficient antifungal action to tinea fungus, and since the therapeutic agent of the present invention comprises as a main component the natural product which is daily drunk in considerable quantities and the safety of which is thus confirmed, the ; 20~8388 therapeutic agent is used without anxiety.
Therefore, the therapeutic agent for tinea according to the present invention has a very high practlcal utility.
The present invention will now be described in detail with reference to the following examples.
Example 1 A 20% (w/v) phosphate buffer extract of cGmmercially available black tea was preapred, and the extract was appropriately diluted and used. Trichophyton mentagroPhYtes TIMM 1188 strain and Trichophyton rubrum TIMM 1216 strain were used as the tinea fungus. The fungus was slant-cultured at 27C for 10 days, and Tween 80 (0.05%)-added physiological saline solution was added to the culture product to separate and float conidiophores. The suspension was filtered through gauze, and a fungus liquid was prepared based on the absorbance at 530 nm by using a turbidimeter (CORONA UT-ll). The following tests were carried out by using this fungus liquid.
1) Antifungal Test An agar plate containing 5% or 2.5% of the tea extract was prepared by using yeast morphology agar (supplied by Difco), and the plate was inoculated with 5 ~Q of the fungus liquid containing 1 x 10 to 1 x 106 of coni-diophores per mQ by the spot method, and culturing was conducted at 27 to 30C for 2 or 4 days and the evaluation 2 0 ~ 8 3 8 8 was made.
As the result, it was found that the tea extract showed apparently an antifungal effect on the tinea fungus, and in the control group, sufficient growth of hyphae was observed by 4 days' culturing, while no growth of hyphae was observed at all in the tea extract-added group.
2) Fungicidal Test Equal amounts of a twice~concentrated Sabouraud culture medium in which conidiophores were floated and a tea extract (5% or 2.5~) were mixed, and culturing was conducted. A Sabouraud agar plate was inoculated with 5 ~Q of the culture medium at predetermined time intervals by the spot method and the growth of the fungus was observed.
As the result, it was found that the fungicidal effect of the tea extract had a concentration dependency, but if the contact time was prolonged (48 to 72 horus), a fungicidal effect was manifested even at a low concen-tration.
Example 2 In Example 1-1), an agar plate in which a predeter-mined amount of epigallocatechin gallate ~EGCg) or theaflavin digallate (TF3) was incorporated instead of the tea extract was prepared, and 5 ~Qof a suspension of 20~8388 conidiophores (1 x 106 7/mQ) was inoculated on the plate by the spot method. Other procedures were the same as in Example 1. The results are shown in Table 1.
` 2018388 ~o ~ + + + +
~o~
E3 ol + + , + +
~1 u~l tn o ~I o + + + +
U
.~_ ~ o + + + +
~0 u~l + I +
O U~
, ~1 , , O
~I ~
R ,:~ ~ ~ ~ ~ O S
~0 ~n .~ ;
~1
Claims (5)
1. A therapeutic agent for tinea, which comprises containing a tea extract as a main component.
2. The therapeutic agent for tinea according to claim 1, wherien effective ingredient of the tea extract is a tea polyphenol.
3. A therapeutic agent for tinea according to claim 2, wherein an amount of the tea polyphenol is 0.1 ? 500 ppm.
4. A method of treating tinea comprising applying to an affected part of a patient an effective amount of tea extract.
5. The method of treating tinea as claimed in claim 4, wherien the tea extract is at least one tea polyphenol selected from the group consisting of (-)epicatechin, (-)epigallocatechin, (-)epicatechingallate, (-)epigallocatechingallate, free theaflavin, theaflavin monogallate A, theaflavin monogallate B and theaflavin digallate.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2047205A JP3019996B2 (en) | 1990-03-01 | 1990-03-01 | Ringworm treatment |
| JP47205/1990 | 1990-03-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2018388A1 true CA2018388A1 (en) | 1991-09-01 |
Family
ID=12768649
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002018388A Abandoned CA2018388A1 (en) | 1990-03-01 | 1990-06-06 | Therapeutic agent for tinea |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US5135957A (en) |
| JP (1) | JP3019996B2 (en) |
| AU (1) | AU617252B2 (en) |
| CA (1) | CA2018388A1 (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3333584B2 (en) * | 1993-04-19 | 2002-10-15 | 三井農林株式会社 | Composition for enhancing acid resistance of teeth |
| US5670154A (en) * | 1994-01-10 | 1997-09-23 | Mitsui Norin Co., Ltd. | Reducing tyrosinase activity |
| JP3213557B2 (en) * | 1996-11-18 | 2001-10-02 | 三井農林株式会社 | A remedy for condyloma acuminatum containing tea catechin as an active ingredient |
| US5968973A (en) * | 1996-11-18 | 1999-10-19 | Cancer Institute (Hospital), Chinese Academy Of Medical Sciences | Method for treating hyperplasia |
| US6197808B1 (en) * | 1996-11-18 | 2001-03-06 | Cancer Instititute (Hospital), Chinese Academy Of Medical Sciences | Methods for treating hyperplasia |
| ES2319626T3 (en) | 2001-11-19 | 2009-05-11 | Medigene Ag | PHARMACO FOR THE TREATMENT OF VIRAL TUMOR AND SKIN DISEASES. |
| US20050079235A1 (en) * | 2003-10-09 | 2005-04-14 | Eggert Stockfleth | Use of a polyphenol for the treatment of actinic keratosis |
| NZ546323A (en) * | 2003-10-09 | 2009-04-30 | Medigene Ag | The use of a polyphenol for the treatment of a cancerous or pre-cancerous lesion of the skin |
| JP5037821B2 (en) * | 2005-12-28 | 2012-10-03 | 三井農林株式会社 | Treatment for ringworm |
| KR101346442B1 (en) * | 2008-06-25 | 2014-01-15 | 바스프 에스이 | Cosmetic compositions, benzotropolone derivatives, and methods for synthesizing benzotropolone derivatives |
| CN101816646B (en) * | 2010-04-27 | 2011-08-03 | 中国人民解放军第二军医大学 | Application of theaflavin as synergist of antifungal medicine |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59219384A (en) * | 1983-05-30 | 1984-12-10 | Mitsui Norin Kk | Preparation of natural antioxidant |
| JPS6013780A (en) * | 1983-07-05 | 1985-01-24 | Mitsui Norin Kk | Production of tea catechin compound |
| JPS61238728A (en) * | 1985-04-16 | 1986-10-24 | Mitsui Norin Kk | Complex substance of extract of tea leaf and active aluminum hydroxide |
| JPS63214183A (en) * | 1987-03-03 | 1988-09-06 | Mitsui Norin Kk | Inhibitor of enzyme transforming angiotensin |
-
1990
- 1990-03-01 JP JP2047205A patent/JP3019996B2/en not_active Expired - Fee Related
- 1990-06-05 US US07/533,463 patent/US5135957A/en not_active Expired - Lifetime
- 1990-06-06 AU AU56827/90A patent/AU617252B2/en not_active Ceased
- 1990-06-06 CA CA002018388A patent/CA2018388A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JPH03255033A (en) | 1991-11-13 |
| AU5682790A (en) | 1991-09-05 |
| AU617252B2 (en) | 1991-11-21 |
| JP3019996B2 (en) | 2000-03-15 |
| US5135957A (en) | 1992-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4840966A (en) | Method of treating hypertension | |
| JP2727471B2 (en) | Influenza virus infection prevention agent | |
| US5135957A (en) | Therapeutic agent for tinea | |
| US5358713A (en) | Method of preventing the transmission of infection caused by methicillin-resistant Staphylococcus aureus | |
| Yang et al. | Inhibition of growth and induction of apoptosis in human cancer cell lines by tea polyphenols. | |
| US5061714A (en) | Isoquinoline composition for the treatment of glaucoma or ocular hypertension | |
| CA2025113C (en) | Agent for preventing infection with antibiotic-resistant staphylococcus | |
| US5470565A (en) | Composition for strengthening acid resistancy of teeth | |
| Winkler et al. | Effect of iodide on total antioxidant status of human serum | |
| EP0415126A1 (en) | Anti-dental plaque agents | |
| EP0393493A3 (en) | Fluorinated bile acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing them | |
| JPH04253918A (en) | Hyperglycemic inhibitor | |
| EP0257113A1 (en) | Use of 2-(2-phenyl-2-(pyridyl))ethyl-2-imidazoline for preparing pharmaceutical preparations for treating and preventing retinopathy | |
| KR100257496B1 (en) | Pharmaceutical composition for the inhibition of bone resorption | |
| US6248346B1 (en) | Chewing gum and production of the same | |
| EP0398720A3 (en) | Piperazine derivatives | |
| CA1139669A (en) | Compositions for treating glaucoma | |
| CA1168154A (en) | Stabilised ophthalmic formulation | |
| WO2005056515A2 (en) | Use of bis-amines to enhance the antimicrobial activity of aqueous compositions | |
| JPH069391A (en) | Hyaluronidase activity inhibitor | |
| JPH0665085A (en) | Tyrosinase activity inhibitor | |
| JP2888554B2 (en) | Mycoplasma infection preventive agent | |
| EP0048944B1 (en) | An antimicrobial preparation | |
| Hine et al. | The toxicity of allylamines | |
| Nahas et al. | Effects and interactions of natural cannabinoids on the isolated heart |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |